4TEEN4 Pharmaceuticals

What 4TEEN4 Pharmaceuticals does

4TEEN4 Pharmaceuticals GmbH is a privately held, clinical-stage German biopharmaceutical company founded in 2013 and headquartered in Hennigsdorf near Berlin, with approximately 11–50 employees. The company is developing a first-in-class therapeutic and companion-diagnostic franchise centered on circulating Dipeptidyl Peptidase 3 (cDPP3), a validated molecular driver and prognostic biomarker of circulatory shock. Its lead candidate, invobenitug (procizumab), is a humanized IgG1 kappa monoclonal antibody designed to selectively neutralize cDPP3, restore renin-angiotensin-aldosterone system (RAAS) balance, stabilize cardiovascular function, and protect organ perfusion in cardiogenic and septic shock patients. Clinical evidence includes favorable Phase 1 safety data in 24 healthy volunteers, three compassionate-use cases showing shock reversal within 48 hours (published in the European Journal of Heart Failure, July 2025), an ongoing multicenter Phase 1b/2a PROCARD1 trial across 11 sites in five European countries (up to 70 patients), FDA IND clearance in June 2026, and the CURE-SHOCK Phase 2a program (150 patients) covering septic, burn, and traumatic shock indications. The company is supported by approximately €64 million in Series C equity (closed February/March 2026), an €8 million Horizon Europe grant, the European Commission STEP Seal, and BMBF/ESF co-funding.

The business model is pre-commercial and capital-driven rather than revenue-driven. Near-term monetization will derive from pharmaceutical product sales and/or licensing of invobenitug upon regulatory approval, complemented by diagnostic revenue streams: a quantitative cDPP3 LIA immunoluminometric assay for cohort testing and biobank services, and the DPP3 InvoSelect lateral-flow companion diagnostic being co-developed with Abingdon Health (legal manufacturer and CDMO) for biomarker-driven patient selection alongside invobenitug. Pricing is not publicly disclosed. The go-to-market approach is enterprise-focused, targeting specialized cardiogenic shock centers and critical care units with direct field engagement, supported by event-driven KOL outreach (e.g., Bio International Convention in San Diego) and a channel-partner strategy with Abingdon Health for diagnostic co-commercialization.

The customer base is currently concentrated on clinical trial investigators and key opinion leaders across EU academic centers; post-approval, the addressable customer base will be highly fragmented across thousands of ICUs treating shock (which accounts for approximately one in three ICU admissions and over 100,000 deaths per year in the US and Europe combined). Key risks include execution risk on Phase 2/3 development, the absence of approved drug therapies for cardiogenic shock in over two decades, regulatory and payer uncertainty for a novel mechanism-of-action biologic, and dependence on continued capital markets and grant funding until first commercial launch.

Name

4TEEN4 Pharmaceuticals

Legal name

4TEEN4 Pharmaceuticals GmbH

Website

https://4teen4.de

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

4TEEN4 Pharmaceuticals GmbH is a clinical-stage German biotech developing invobenitug (procizumab), a first-in-class monoclonal antibody neutralizing circulating DPP3 to treat cardiogenic and septic shock, paired with a companion diagnostic for biomarker-driven patient selection in critical care.

Ownership category

akta.pro rank

Product category

Critical Care Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)

Keywords

• Monoclonal antibody therapy
• Cardiogenic shock treatment
• Circulatory shock therapeutics
• Companion diagnostics
• Critical care biopharmaceuticals

Headquarters

HQ city

Hennigsdorf

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Licensing/Royalties: Pre-commercial stage. The company is developing a novel monoclonal antibody therapeutic for cardiogenic and septic shock. Upon regulatory approval, revenue would be generated through product sales and potential licensing agreements.
2. Diagnostic Testing Services: The company offers cDPP3 cohort analysis services for biobank samples using their LIA assay, as well as collaborative partnerships for establishing cDPP3 testing in clinical routine.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

4TEEN4 Pharmaceuticals develops invobenitug (procizumab), a first-in-class humanized monoclonal antibody that selectively neutralizes circulating Dipeptidyl Peptidase 3 (cDPP3) to treat life-threatening cardiogenic, septic, burn, and traumatic shock. The therapeutic is paired with companion diagnostics (DPP3 InvoSelect lateral-flow test and cDPP3 LIA assay) that enable biomarker-driven patient stratification. The company also offers cDPP3 cohort testing services for biobank samples and clinical research collaborations.

Product overview

4TEEN4 Pharmaceuticals is developing a therapeutic and diagnostic portfolio centered on the cDPP3 (circulating dipeptidyl peptidase 3) pathway. The core product is invobenitug (procizumab), a first-in-class humanized monoclonal antibody therapeutic that neutralizes cDPP3 to treat cardiogenic and septic shock. This therapeutic is supported by DPP3 InvoSelect, a companion diagnostic for identifying patients with elevated cDPP3 levels who may benefit from treatment. The company also offers cDPP3 cohort testing services using its LIA assay for biomarker research.

Differentiator

Problem solved

Functional benefit

Products and services

• Invobenitug (procizumab) First-in-class humanized IgG1 kappa monoclonal antibody that selectively neutralizes circulating dipeptidyl peptidase 3 (cDPP3) to restore RAAS balance, stabilize cardiovascular function, and protect vital organs in patients with cardiogenic, septic, burn, and traumatic shock. Currently in Phase 1b/2a clinical development.
• DPP3 InvoSelect Companion Diagnostic Lateral flow-based companion diagnostic co-developed with Abingdon Health to detect cDPP3 levels in patients and enable biomarker-driven patient selection for invobenitug therapy targeting life-threatening cardiogenic and septic shock.
• cDPP3 LIA Assay Immunoluminometric assay (LIA) for reliable quantification of DPP3 protein concentration in human plasma, used for cohort testing and clinical biomarker measurement with a 30 ng/mL cutoff to identify patients with DPP3-driven circulatory failure.
• cDPP3 Cohort Testing Service

Quantifiable outcome

• In preclinical septic shock models, procizumab reduced catecholamine and fluid requirements while preserving organ perfusion
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Abingdon HealthcoreStrategic or Co-development Partner · 6 May 2026Partnership for co-development of DPP3 InvoSelect, a lateral flow-based companion diagnostic for invobenitug antibody therapy targeting cardiogenic and septic shock. Abingdon Health serves as legal manufacturer and CDMO partner, aligning assay development, regulatory strategy, and scale-up manufacturing with 4TEEN4's drug development timeline for global deployment. The partnership has reached the design freeze milestone and is preparing for performance evaluation alongside pivotal clinical trials.
• University Medical Center Hamburg-Eppendorf (UKE)coreStrategic or Co-development PartnerLead institution for CURE-SHOCK Phase 2a clinical trial in collaboration with UKSH Lübeck, Centrum Leczenia Oparzen (Poland), Bogomolets National Medical University (Ukraine), and 4TEEN4 Pharmaceuticals.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Adrenomed AG: German biotech developing adrecizumab, a monoclonal antibody targeting adrenomedullin in septic shock, with a biomarker-driven patient-selection strategy. Highly comparable to 4TEEN4's anti-cDPP3 antibody + companion diagnostic approach for critical care; CEO Bergmann is a former Adrenomed executive.
• Inotrem: France-based clinical-stage biotech developing nangibotide (a TREM-1 inhibitor peptide) for septic shock, with biomarker-stratified Phase 2 trials in ICU settings. Closely comparable to 4TEEN4 in target indication, trial design philosophy, and precision-medicine positioning.
• Spectral Medical: Toronto-listed company developing Toraymyxin (PMX) for endotoxemic septic shock and a complementary diagnostic (EAA) for patient selection. Comparable as a therapeutic-plus-diagnostic critical-care play targeting high-mortality shock with a precision-medicine approach.
• CytoSorbents: US-listed company commercializing CytoSorb, a blood-purification cartridge used in ICU settings for cytokine storm, sepsis, and shock. Comparable as a critical-care therapy targeting shock-related mortality and ICU resource utilization.
• Sphingotec GmbH: German diagnostics company developing and commercializing novel biomarkers for critical care, including DPP3-related assays. Closely comparable to 4TEEN4's biomarker and LIA assay business, and shares founder/management lineage with 4TEEN4.

Broad incumbents

• Abiomed (Johnson & Johnson MedTech): Acquired by Johnson & Johnson, Abiomed markets the Impella family of percutaneous ventricular assist devices for cardiogenic shock. Comparable as an incumbent in cardiogenic shock treatment with overlapping ICU customers, though addressing a different (mechanical circulatory support) mechanism.
• BioMérieux: Global in vitro diagnostics leader with extensive ICU and sepsis biomarker menu including procalcitonin. Comparable as an established diagnostics player serving the same ICU customer base and biomarker-guided decision-making workflows targeted by DPP3 InvoSelect.
• F. Hoffmann-La Roche: Global pharmaceutical and diagnostics company with critical-care and cardiology franchises plus a major companion-diagnostics business. Comparable as a potential large-pharma acquirer/partner for a shock therapeutic plus CDx, given Roche's dual drug-diagnostic capabilities.

Emerging players

• Cardior Pharmaceuticals: Hannover-based cardiac biotech acquired by Novo Nordisk in 2024 for approximately €1bn, focused on RNA-based therapeutics for heart failure. Comparable as a European cardiovascular biotech with similar partnership/exit dynamics and shared senior leadership.
• Abingdon Health: UK-based lateral-flow assay developer and CDMO serving as 4TEEN4's manufacturing and regulatory partner for DPP3 InvoSelect. Comparable as the CDx partner and as a lateral-flow diagnostics specialist addressing similar point-of-care critical-care applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/4teen4-pharmaceuticals

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds10 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4TEEN4 Pharmaceuticals